GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (FRA:NO1A) » Definitions » Cyclically Adjusted Price-to-FCF

Navidea Biopharmaceuticals (FRA:NO1A) Cyclically Adjusted Price-to-FCF : (As of May. 21, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Navidea Biopharmaceuticals Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Navidea Biopharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Navidea Biopharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Navidea Biopharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Navidea Biopharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navidea Biopharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Navidea Biopharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Navidea Biopharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Navidea Biopharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Navidea Biopharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.1/129.8595*129.8595
=-0.100

Current CPI (Sep. 2023) = 129.8595.

Navidea Biopharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -1.270 98.326 -1.677
201403 -1.015 99.695 -1.322
201406 -0.839 100.560 -1.083
201409 -0.698 100.428 -0.903
201412 -0.525 99.070 -0.688
201503 -0.508 99.621 -0.662
201506 -0.797 100.684 -1.028
201509 -0.488 100.392 -0.631
201512 -0.499 99.792 -0.649
201603 -0.195 100.470 -0.252
201606 0.037 101.688 0.047
201609 0.304 101.861 0.388
201612 0.275 101.863 0.351
201703 7.674 102.862 9.688
201706 -0.623 103.349 -0.783
201709 -0.098 104.136 -0.122
201712 -0.199 104.011 -0.248
201803 -0.226 105.290 -0.279
201806 1.110 106.317 1.356
201809 -0.194 106.507 -0.237
201812 -0.197 105.998 -0.241
201903 -0.191 107.251 -0.231
201906 -0.169 108.070 -0.203
201909 -0.118 108.329 -0.141
201912 -0.134 108.420 -0.160
202003 -0.045 108.902 -0.054
202006 -0.082 108.767 -0.098
202009 -0.093 109.815 -0.110
202012 -0.081 109.897 -0.096
202103 -0.094 111.754 -0.109
202106 -0.070 114.631 -0.079
202109 -0.061 115.734 -0.068
202112 -0.083 117.630 -0.092
202203 -0.080 121.301 -0.086
202206 -0.071 125.017 -0.074
202209 -0.064 125.227 -0.066
202212 -0.073 125.222 -0.076
202303 -0.050 127.348 -0.051
202306 0.088 128.729 0.089
202309 -0.100 129.860 -0.100

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Navidea Biopharmaceuticals  (FRA:NO1A) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Navidea Biopharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Navidea Biopharmaceuticals (FRA:NO1A) Business Description

Traded in Other Exchanges
Address
4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.

Navidea Biopharmaceuticals (FRA:NO1A) Headlines

No Headlines